Tonix director granted options on 22,700 shares

Tonix Pharmaceuticals Holding Corp. reported that director Carolyn E. Taylor received a grant of stock options covering 22,700 shares of common stock.

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. reported that director Carolyn E. Taylor received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036.

The award was granted under Tonix’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the May 12, 2026 grant date and the company’s 2027 Annual Meeting of Stockholders. Following this grant, Taylor holds stock options for 22,700 shares as reported in this filing.

Insider Trade Summary

Grant/Award: 22,700 shares

Grant/Award 1 txn

Insider Taylor Carolyn E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	22,700	$0.00	$0.00

Holdings After Transaction: Stock Option — 22,700 contracts (Direct)

Footnotes (1)

1. F1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.

Key Figures

Option grant size: 22,700 shares Exercise price: $13.28 per share Options held after grant: 22,700 options +2 more

5 metrics

Option grant size 22,700 shares Stock options granted on May 12, 2026

Exercise price <money>$13.28</money> per share Stock option strike price

Options held after grant 22,700 options Total derivative holdings following transaction

Expiration date <date>May 12, 2036</date> Option term under 2026 Stock Incentive Plan

Vesting trigger Earlier of 1-year anniversary or 2027 meeting Vesting condition from plan footnote

Key Terms

Stock Option, 2026 Stock Incentive Plan, exercise price, vesting, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2026 Stock Incentive Plan financial

"The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan"

exercise price financial

"conversion_or_exercise_price: "13.2800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"vests on the earlier of the one year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-05-12T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tonix (TNXP) director Carolyn E. Taylor receive in this Form 4 filing?

Carolyn E. Taylor received a grant of stock options for 22,700 shares of Tonix common stock. The award is a compensation-related option grant under the 2026 Stock Incentive Plan, not an open-market purchase or sale, and increases her derivative holdings accordingly.

What is the exercise price of Carolyn E. Taylor’s Tonix (TNXP) stock options?

The stock options granted to Carolyn E. Taylor have an exercise price of $13.28 per share. This is the price she must pay to purchase each share upon exercise, as long as the options are vested and exercised before their expiration date in 2036.

When do Carolyn E. Taylor’s Tonix (TNXP) stock options vest?

The options vest on the earlier of the one-year anniversary of the May 12, 2026 grant date and Tonix’s 2027 Annual Meeting of Stockholders. This means vesting is tied to both time in service and the timing of the 2027 stockholder meeting.

When do the Tonix (TNXP) stock options granted to Carolyn E. Taylor expire?

The options granted to Carolyn E. Taylor expire on May 12, 2036. She may exercise vested options any time before that expiration date, subject to the terms of Tonix’s 2026 Stock Incentive Plan and any applicable service or board requirements.

How many Tonix (TNXP) stock options does Carolyn E. Taylor hold after this grant?

After this grant, Carolyn E. Taylor is reported as holding stock options covering 22,700 shares of Tonix common stock. The entire amount comes from this single award, as reflected by the total derivative holdings figure in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Carolyn E.

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.28	05/12/2026		A		22,700		05/12/2027(1)	05/12/2036	Common Stock	22,700	$0.00(1)	22,700	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.

	/s/ Jessica Morris, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)